Udviklingen af disse antistoffer er sædvanligvis ikke forbundet med tab af klinisk effekt, selvom deres tilstedeværelse efter langtids- behandling med calcitonin hos en lille procentdel af patienterne kan medføre nedsat respons over for præparatet.
The development of these antibodies is not usually related to loss of clinical efficacy, although their presence in a small percentage of patients following long-term therapy with calcitonin may result in a reduced response to the product.